Side by side
KPV vs Thymosin alpha-1
Both are discussed for healing & recovery. What this site records about each, side by side. Every figure is on the compound's own page with the source it came from.
| KPV | Thymosin alpha-1 | |
|---|---|---|
| What it is | A three-amino-acid fragment of alpha-MSH studied for anti-inflammatory effects, largely in animal models of gut inflammation. | An immune-modulating peptide approved in more than thirty countries for hepatitis B, and studied in sepsis and as a vaccine adjuvant. Not approved in the United States. |
| EvidenceHow much human evidence exists, not how well it works. | Preclinical | Approved for another indication |
| Regulatory statusReviewed 2026-08-12 | Not approved for human use in the United States. Sold only as a research chemical. | Approved as thymalfasin in more than thirty countries, principally for chronic hepatitis B. Not approved in the United States, where it is sold as a research chemical with no manufacturing standard behind it. |
| Routes | Subcutaneous, Oral, Topical | Subcutaneous |
| Half-life | 1 hours | 2 hours |
| Cheapest per mgVials only, read from vendors' own listings and dated on the price index. | $1.40/mg | $2.00/mg |
| Median per mg | $4.50/mg | $7.20/mg |
| Vendors with a price | 52 | 43 |
| Storage once mixed | Refrigerated at 2–8 °C. Do not freeze once mixed. | Refrigerated at 2–8 °C. Do not freeze once mixed. |
Compare two other compounds · The full price index
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on BioAlmanac is medical advice. Nothing here ranks these two against each other. A table can show that one has more human evidence behind it or costs less per milligram; neither of those is a recommendation, and the right comparison for any person is one their doctor makes with them.